Equities researchers at Dawson James started coverage on shares of STRATA Skin Sciences (NASDAQ:SSKN) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating on the medical device company’s stock.

SSKN has been the subject of a number of other reports. HC Wainwright set a $3.00 price objective on shares of STRATA Skin Sciences and gave the company a “buy” rating in a research note on Thursday, May 31st. Zacks Investment Research lowered shares of STRATA Skin Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Finally, ValuEngine raised shares of STRATA Skin Sciences from a “hold” rating to a “buy” rating in a report on Thursday, July 5th.

STRATA Skin Sciences stock traded down $0.19 during mid-day trading on Tuesday, reaching $2.48. The company’s stock had a trading volume of 7,268 shares, compared to its average volume of 306,276. STRATA Skin Sciences has a 12-month low of $1.06 and a 12-month high of $2.86. The firm has a market capitalization of $79.80 million, a price-to-earnings ratio of 1.26 and a beta of 0.67. The company has a current ratio of 4.77, a quick ratio of 4.20 and a debt-to-equity ratio of 0.22.

STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings data on Monday, August 13th. The medical device company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. STRATA Skin Sciences had a negative net margin of 63.07% and a negative return on equity of 27.01%. The business had revenue of $7.53 million during the quarter, compared to analyst estimates of $6.84 million. equities research analysts forecast that STRATA Skin Sciences will post -0.26 EPS for the current year.

In other news, Director Luann Via purchased 25,000 shares of the business’s stock in a transaction on Friday, June 8th. The stock was purchased at an average cost of $2.14 per share, with a total value of $53,500.00. Following the acquisition, the director now directly owns 5,000 shares in the company, valued at $10,700. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders acquired 40,000 shares of company stock valued at $82,850. Insiders own 9.95% of the company’s stock.

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in STRATA Skin Sciences by 80.0% in the 4th quarter. Renaissance Technologies LLC now owns 95,620 shares of the medical device company’s stock valued at $118,000 after purchasing an additional 42,500 shares during the period. Macquarie Group Ltd. boosted its holdings in STRATA Skin Sciences by 89.7% in the 2nd quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after purchasing an additional 63,393 shares during the period. Menora Mivtachim Holdings LTD. bought a new position in STRATA Skin Sciences in the 2nd quarter valued at $1,138,000. Finally, Nantahala Capital Management LLC bought a new position in STRATA Skin Sciences in the 2nd quarter valued at $4,261,000. 27.47% of the stock is owned by hedge funds and other institutional investors.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

See Also: Hedge Funds – How They Work For Investors

The Fly

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.